Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients

R Lee Mosley, Paul H. Gordon, Christopher M. Hasiak, Francis J. Van Wetering, Hiroshi Mitsumoto, Howard Eliot Gendelman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We assessed humoral and cytokine responses in monthly plasma samples from ALS patients who received glatiramer acetate (GA) immunization every day or every other week, or remained untreated (control) from a six-month phase II trial. Samples were evaluated by GA-specific ELISA assays for detection of combined immunoglobulin (Ig) classes (IgM,A,G), IgG alone, and IgG subclasses (IgG1, IgG2, IgG3, and IgG4). T-helper (Th) type 1 and 2 (Th1 and Th2) cytokine levels were determined by flow cytometric cytokine bead arrays. Fourteen of 21 GA-immunized patients produced anti-GA Ig responses. Those treated every day produced anti-GA responses within one month, while those treated every other week exhibited responses by month two. All anti-GA IgG subclass concentrations were increased in excess of 4.2-fold in plasma from treated patients, and anti-GA IgG1 comprised the majority of the humoral response. Mean plasma cytokine levels were statistically indistinguishable between treatment regimens; however, stratification by patient and time on study showed more prevalent trends in changes of Th1 or Th2 cytokine levels following GA treatment every other week or every day, respectively. These data show significant humoral responses and cytokine trends following GA immunization in ALS patients.

Original languageEnglish (US)
Pages (from-to)235-242
Number of pages8
JournalAmyotrophic Lateral Sclerosis
Volume8
Issue number4
DOIs
StatePublished - Aug 7 2007

Fingerprint

Antibody Formation
Immunization
Cytokines
Immunoglobulin G
Glatiramer Acetate
Immunoglobulin Isotypes
Immunoglobulin M
Immunoglobulins
Enzyme-Linked Immunosorbent Assay
Therapeutics

Keywords

  • Antibodies
  • Copaxone
  • Cytokines
  • Glatiramer acetate
  • Th1/Th2

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients. / Mosley, R Lee; Gordon, Paul H.; Hasiak, Christopher M.; Van Wetering, Francis J.; Mitsumoto, Hiroshi; Gendelman, Howard Eliot.

In: Amyotrophic Lateral Sclerosis, Vol. 8, No. 4, 07.08.2007, p. 235-242.

Research output: Contribution to journalArticle

Mosley, R Lee ; Gordon, Paul H. ; Hasiak, Christopher M. ; Van Wetering, Francis J. ; Mitsumoto, Hiroshi ; Gendelman, Howard Eliot. / Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients. In: Amyotrophic Lateral Sclerosis. 2007 ; Vol. 8, No. 4. pp. 235-242.
@article{eba71a1604794b3cb812744bc8107390,
title = "Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients",
abstract = "We assessed humoral and cytokine responses in monthly plasma samples from ALS patients who received glatiramer acetate (GA) immunization every day or every other week, or remained untreated (control) from a six-month phase II trial. Samples were evaluated by GA-specific ELISA assays for detection of combined immunoglobulin (Ig) classes (IgM,A,G), IgG alone, and IgG subclasses (IgG1, IgG2, IgG3, and IgG4). T-helper (Th) type 1 and 2 (Th1 and Th2) cytokine levels were determined by flow cytometric cytokine bead arrays. Fourteen of 21 GA-immunized patients produced anti-GA Ig responses. Those treated every day produced anti-GA responses within one month, while those treated every other week exhibited responses by month two. All anti-GA IgG subclass concentrations were increased in excess of 4.2-fold in plasma from treated patients, and anti-GA IgG1 comprised the majority of the humoral response. Mean plasma cytokine levels were statistically indistinguishable between treatment regimens; however, stratification by patient and time on study showed more prevalent trends in changes of Th1 or Th2 cytokine levels following GA treatment every other week or every day, respectively. These data show significant humoral responses and cytokine trends following GA immunization in ALS patients.",
keywords = "Antibodies, Copaxone, Cytokines, Glatiramer acetate, Th1/Th2",
author = "Mosley, {R Lee} and Gordon, {Paul H.} and Hasiak, {Christopher M.} and {Van Wetering}, {Francis J.} and Hiroshi Mitsumoto and Gendelman, {Howard Eliot}",
year = "2007",
month = "8",
day = "7",
doi = "10.1080/17482960701374601",
language = "English (US)",
volume = "8",
pages = "235--242",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients

AU - Mosley, R Lee

AU - Gordon, Paul H.

AU - Hasiak, Christopher M.

AU - Van Wetering, Francis J.

AU - Mitsumoto, Hiroshi

AU - Gendelman, Howard Eliot

PY - 2007/8/7

Y1 - 2007/8/7

N2 - We assessed humoral and cytokine responses in monthly plasma samples from ALS patients who received glatiramer acetate (GA) immunization every day or every other week, or remained untreated (control) from a six-month phase II trial. Samples were evaluated by GA-specific ELISA assays for detection of combined immunoglobulin (Ig) classes (IgM,A,G), IgG alone, and IgG subclasses (IgG1, IgG2, IgG3, and IgG4). T-helper (Th) type 1 and 2 (Th1 and Th2) cytokine levels were determined by flow cytometric cytokine bead arrays. Fourteen of 21 GA-immunized patients produced anti-GA Ig responses. Those treated every day produced anti-GA responses within one month, while those treated every other week exhibited responses by month two. All anti-GA IgG subclass concentrations were increased in excess of 4.2-fold in plasma from treated patients, and anti-GA IgG1 comprised the majority of the humoral response. Mean plasma cytokine levels were statistically indistinguishable between treatment regimens; however, stratification by patient and time on study showed more prevalent trends in changes of Th1 or Th2 cytokine levels following GA treatment every other week or every day, respectively. These data show significant humoral responses and cytokine trends following GA immunization in ALS patients.

AB - We assessed humoral and cytokine responses in monthly plasma samples from ALS patients who received glatiramer acetate (GA) immunization every day or every other week, or remained untreated (control) from a six-month phase II trial. Samples were evaluated by GA-specific ELISA assays for detection of combined immunoglobulin (Ig) classes (IgM,A,G), IgG alone, and IgG subclasses (IgG1, IgG2, IgG3, and IgG4). T-helper (Th) type 1 and 2 (Th1 and Th2) cytokine levels were determined by flow cytometric cytokine bead arrays. Fourteen of 21 GA-immunized patients produced anti-GA Ig responses. Those treated every day produced anti-GA responses within one month, while those treated every other week exhibited responses by month two. All anti-GA IgG subclass concentrations were increased in excess of 4.2-fold in plasma from treated patients, and anti-GA IgG1 comprised the majority of the humoral response. Mean plasma cytokine levels were statistically indistinguishable between treatment regimens; however, stratification by patient and time on study showed more prevalent trends in changes of Th1 or Th2 cytokine levels following GA treatment every other week or every day, respectively. These data show significant humoral responses and cytokine trends following GA immunization in ALS patients.

KW - Antibodies

KW - Copaxone

KW - Cytokines

KW - Glatiramer acetate

KW - Th1/Th2

UR - http://www.scopus.com/inward/record.url?scp=34547602961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547602961&partnerID=8YFLogxK

U2 - 10.1080/17482960701374601

DO - 10.1080/17482960701374601

M3 - Article

C2 - 17653922

AN - SCOPUS:34547602961

VL - 8

SP - 235

EP - 242

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - 4

ER -